Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
